IN THE CLAIMS:

Claims 30-32 and 39-44 are pending in the application. The claims are reiterated for the convenience of the Examiner.

30. (Twice Amended) An immunoadhesin comprising a polypeptide and an immunoglobulin amino acid sequence, the polypeptide comprising an amino acid sequence of the EGF-like domain of SEQ ID NO:4, wherein the polypeptide binds to ErbB4 receptor and activates receptor tyrosine phosphorylation of the ErbB4 receptor.

31. (Reiterated) The immunoadhesin of claim 30 wherein the immunoglobulin sequence is an immunoglobulin heavy chain constant domain sequence.

32. (Reiterated) The immunoadhesin of claim 31 wherein the immunoglobulin sequence is a constant domain sequence of an IgG-1, IgG-2 or IgG-3.

39. (Amended) The [polypeptide]immunoadhesin of claim 30[encoded by a], wherein the polypeptide is encoded by a nucleic acid sequence comprising nucleic acids 1150 to and including 1290 of the NRG3 nucleic acid open reading frame sequence [in ATCC deposit 209156 (pLXSN.mNRG3)]SEQ ID NO:1.

40. (Amended) The [polypeptide]immunoadhesin of claim 30[encoded by a], wherein the polypeptide is encoded by a nucleic acid sequence comprising nucleic acids 999 to and including 1139 of the NRG3 nucleic acid open reading frame sequence [in ATCC deposit 209157 (pRK5.tk.neo.hNRG3B1)]SEQ ID NO:5.

41. (Amended) The [polypeptide]immunoadhesin of claim 30[encoded by a], wherein the polypeptide is encoded by a nucleic acid sequence comprising nucleic acids 856 to and including 996 of the NRG3 nucleic acid open reading frame sequence [in ATCC deposit 209155 (pRK5.tk.neo.hNRG3B2)]SEQ ID NO:22.

42. (Amended) The [polypeptide]immunoadhesin of claim 30, wherein the polypeptide [which] is devoid of a cytoplasmic domain, or devoid of a transmembrane domain that can anchor the polypeptide in